Puma Biotechnology Competitors and Similar CompaniesClear all
Puma Biotechnology's competitors and similar companies include ImmunoGen, Takeda, Oncopeptides and Ascendis Pharma.
 Puma Biotechnology Puma Biotechnology acquires and develops innovative products for the treatment of various forms of cancer. |  ImmunoGen ImmunoGen is a biotechnology company focused on the development of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. |  Takeda Takeda Pharmaceutical (武田薬品工業株式会社) is a biopharmaceutical company engaged in the research, development, production, and commercialization of pharmaceutical products. |  Ascendis Pharma Ascendis Pharma is a biopharmaceutical company that specializes in endocrinology and oncology. | ||
Founding Date | Founding Date 2010 | Founding Date 1981 | Founding Date 1781 | Founding Date 2000 | Founding Date 2007 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Los Angeles, US HQ | Locations Waltham, US HQ | Locations Stockholm, SE HQ Stockholm, SE Los Altos, US Mountain View, US Waltham, US | Locations Hellerup, DK HQ Heidelberg, DE Palo Alto, US | |
Employees | Employees 27214% decrease | Employees 277161% increase | Employees 47,4554% decrease | Employees 80 | Employees 1,017 |
Valuation ($) | Valuation ($) 136.8 m | Valuation ($) 8.7 b | Valuation ($) 43.7 b | Valuation ($) 42.4 m | Valuation ($) 7.7 b |
Financial | |||||
Revenue (est.) | Revenue (est.) $228.4m (FY, 2025) | Revenue (est.) $108.8m (FY, 2022) | Revenue (est.) ¥4.6t (FY, 2025) | Revenue (est.) kr71.1m (FY, 2025) | Revenue (est.) €720.1m (FY, 2025) |
Cost of goods | Cost of goods $58.2m (FY, 2025) | Cost of goods $176k (FY, 2022) | Cost of goods ¥818.8b (FY, 2025) | Cost of goods kr2.5m (FY, 2025) | Cost of goods €93.1m (FY, 2025) |
Gross profit | Gross profit $170.2m (FY, 2025) | Gross profit $108.6m (FY, 2022) | Gross profit ¥3.8t (FY, 2025) | Gross profit kr72m (FY, 2025) | Gross profit €627.1m (FY, 2025) |
Net income | Net income N/A | Net income ($222.9m) (FY, 2022) | Net income ¥108.1b (FY, 2025) | Net income (kr249.6m) (FY, 2025) | Net income (€228m) (FY, 2025) |
Funding | |||||
Total funding raised | Total funding raised $ 172m | Total funding raised $ 56m | Total funding raised $ 57.8m | Total funding raised N/A | Total funding raised $ 85.8m |
For sources of this data, please see the company profile
View Company Profiles
ImmunoGen
HQ
Waltham, US
Employees
277
ImmunoGen is a biotechnology company focused on the development of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients.
View companyTakeda
HQ
Tokyo, JP
Employees
47,455↓ 4% decrease
Takeda Pharmaceutical (武田薬品工業株式会社) is a biopharmaceutical company engaged in the research, development, production, and commercialization of pharmaceutical products.
View company
Oncopeptides
HQ
Stockholm, SE
Employees
80
Oncopeptides is a clinical development pharmaceutical company.
View companyAscendis Pharma
HQ
Hellerup, DK
Employees
1,017
Ascendis Pharma is a biopharmaceutical company that specializes in endocrinology and oncology.
View company